At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Sparsentandrug
Likely dose
Sparsentan 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With Immunoglobulin A Nephropathy (IgAN)
In Brief
A Phase 2 clinical trial evaluating Sparsentan for Immunoglobulin A Nephropathy. Completed, enrolled 48 participants across 30 sites in 2 countries.
Detailed Summary
This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunoglobulin A Nephropathy
CountriesHong Kong, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedMay 2023
Enrollment StartMay 2023
Primary CompletionOct 2024
Study CompletionOct 2024
TodayJul 2026
First PostedMay 12, 2023
Enrollment StartMay 19, 2023
Primary CompletionOct 14, 2024
Study CompletionOct 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.1 years ago
Interventions
Sparsentandrug
Target dose of 400 mg daily